-
November 25, 2011
England and Wales' cost watchdog has rejected Merck KGaA’s Erbitux, Roche’s Avastin and Amgen's Vectibix as second-line treatments for advanced colon cancer
Full story
-
November 14, 2011
Shares in Alimera Sciences have taken a hammering after regulators in the USA rejected Iluvien, the firms' treatment for diabetic macular oedema
Full story
-
November 11, 2011
The cost watchdog has reiterated its view that AstraZeneca's breast cancer drug Faslodex does not represent good use of NHS resources and is not proven to be better than existing treatments.
Full story
-
July 21, 2011
The ABPI has taken the unusual step of speaking out in the wake of the NICE's recommendation to reject Eisai's advanced breast cancer drug Halaven
Full story
-
November 25, 2010
Cost regulators for the NHS in England and Wales have again rejected Roche's Tarceva as a maintenance therapy for NSCLC, a decision which has disappointed the Swiss drugs major
Full story
-
October 20, 2010
Amylin and Eli Lilly, plus partner Alkermes have suffered a major setback with the news that regulators in the USA have turned down Bydureon, the firm's long-acting, once-weekly version of the diabetes blockbuster Byetta
Full story